These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8374564)

  • 1. Bone marrow transplantation for children with thalassemia: two years' experience with low-dose busulfan, citoxan and GM-CSF.
    Miniero R; Vassallo E; Busca A; Piga A; Perugini L; Madon E
    Bone Marrow Transplant; 1993; 12 Suppl 1():51-3. PubMed ID: 8374564
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone marrow transplantation in thalassemia. The Cagliari team experience.
    Contu L; La Nasa G; Pizzati A; Arras M; Vacca A; Ledda A; Carcassi C; Orrù S; Mulargia M; Boero R
    Bone Marrow Transplant; 1993; 12 Suppl 1():45-6. PubMed ID: 8374560
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone marrow transplantation for thalassemia in Hong Kong: the early experience.
    Lee AC; Lau YL; Chan CF; Chiu E; Liang R; Chan TK; Yeung CY
    Bone Marrow Transplant; 1993; 12 Suppl 1():49-50. PubMed ID: 8374562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients.
    Manna M; Nesci S; Andreani M; Tonucci P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():70-3. PubMed ID: 8104074
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome.
    Chandy M; Balasubramanian P; Ramachandran SV; Mathews V; George B; Dennison D; Krishnamoorthy R; Srivastava A
    Bone Marrow Transplant; 2005 Nov; 36(10):839-45. PubMed ID: 16151422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.
    Calderwood S; Doyle JJ; Hitzler JK; Saunders EF; Freedman MH
    Bone Marrow Transplant; 1996 Jul; 18(1):87-91. PubMed ID: 8832000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic beta-cell function before and after bone marrow transplantation for thalassemia.
    Galimberti M; De Sanctis V; Lucarelli G; Polchi P; Angelucci E; Baronciani D; Giardini C; Erer B; Gaziev J; Balducci R
    Bone Marrow Transplant; 1993; 12 Suppl 1():102-3. PubMed ID: 8374544
    [No Abstract]   [Full Text] [Related]  

  • 10. Bone marrow transplantation in class 2 thalassemia patients.
    Giardini C; Galimberti M; Lucarelli G; Polchi P; Baronciani D; Angelucci E
    Bone Marrow Transplant; 1993; 12 Suppl 1():59-62. PubMed ID: 8374566
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial.
    Visani G; Gamberi B; Greenberg P; Advani R; Gulati S; Champlin R; Hoglund M; Karanes C; Williams S; Keating A
    Bone Marrow Transplant; 1991; 7 Suppl 2():81. PubMed ID: 1878732
    [No Abstract]   [Full Text] [Related]  

  • 12. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
    Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
    Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF approved for treatment of bone marrow transplant failure.
    Oncology (Williston Park); 1992 Feb; 6(2):53. PubMed ID: 1532502
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadal function in long term survivors with B thalassemia major following bone marrow transplantation.
    De Sanctis V; Galimberti M; Lucarelli G; Angelucci E; Ughi M; Baronciani D; Polchi P; Giardini C; Vullo C; Bagni B
    Bone Marrow Transplant; 1993; 12 Suppl 1():104. PubMed ID: 8374545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.